Gene Ontology annotation through association of InterPro records with GO terms
Gene Ontology annotation based on Enzyme Commission mapping
Annotation inferences using phylogenetic trees
Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping, accompanied by conservative changes to GO terms applied by UniProt
Gene Ontology annotation based on curation of immunofluorescence data
Automatic transfer of experimentally verified manual GO annotation data to orthologs using Ensembl Compara
Electronic Gene Ontology annotations created by ARBA machine learning models
RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor.
Defining the membrane proteome of NK cells.
Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders.
Analysis of the myosin-II-responsive focal adhesion proteome reveals a role for β-Pix in negative regulation of focal adhesion maturation.
Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling
KIF14 negatively regulates Rap1a-Radil signaling during breast cancer progression.
Desmoglein-1/Erbin interaction suppresses ERK activation to support epidermal differentiation.
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.
The chaperone protein SmgGDS interacts with small GTPases entering the prenylation pathway by recognizing the last amino acid in the CAAX motif.
A proteome-scale map of the human interactome network.
Integrative analysis of kinase networks in TRAIL-induced apoptosis provides a source of potential targets for combination therapy.
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.
-
Common KRAS cancer mutants were characterized for nucleotide binding, intrinsic/GAP-stimulated GTPase activity, and RAF interaction.
"we characterized the most common KRAS mutants biochemically for substrate binding kinetics, intrinsic and"
SIRT2 and lysine fatty acylation regulate the transforming activity of K-Ras4a.
Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability.
Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRAS(G13D).
KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation.
Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex.
Structure of the SHOC2-MRAS-PP1C complex provides insights into RAF activation and Noonan syndrome.
-
MRAS is the preferred SHOC2-PP1C partner, while HRAS, KRAS, and NRAS can also bind with lower affinity.
"The canonical RAS family members HRAS, KRAS, and NRAS (H/K/NRAS) also bind SHOC2"
Studying early structural changes in SOS1 mediated KRAS activation mechanism.
Allosteric nanobodies to study the interactions between SOS1 and RAS.
Structural insights into isoform-specific RAS-PI3Kα interactions and the role of RAS in PI3Kα activation.
p-RasGRP1,3:DAG cause RAS to exchange GDP for GTP
SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with ligand-responsive p-6Y-EGFR mutants)
SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with phosphorylated SHC1 and ligand-responsive p-6Y-EGFR mutants)
RAS guanyl-nucleotide exchange mediated by SOS1 in complex with GRB2 and p-Y349,350-SHC1:p-ERBB4
RAS guanyl nucleotide exchange mediated by SOS1 bound to GRB2 in complex with phosphorylated ERBB4:ERBB2 heterodimers
Activation of RAS by p-KIT bound SOS1
SOS1-mediated nucleotide exchange of RAS (EGF:EGFR:GRB2:SOS1)
SOS1-mediated nucleotide exchange of RAS (EGF:EGFR:SHC1:GRB2:SOS1)
SOS-mediated nucleotide exchange on RAS (PDGF receptor:GRB2:SOS)
Sos-mediated nucleotide exchange of Ras (Tie2 receptor:Grb2:Sos)
SOS1-mediated nucleotide exchange of RAS (HB-EFG-initiated)
SOS mediated nucleotide exchange of RAS (SHC)
NCAM1:pFAK:Grb2:Sos-mediated nucleotide exchange of Ras
p-SPHK1 phosphorylates sphingosine to sphingosine 1-phosphate
CD209 activate GTPase RAS
SFKs phosphorylates RAF1 on Y340,Y341
PAK phosphorylates p21 RAF1 on S338
SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with p-EGFRvIII)
SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with phosphorylated SHC1 and p-EGFRvIII)
Activated FGFR1:p-FRS:GRB2:SOS1 activates RAS nucleotide exchange
Activated FGFR2:p-SHC1:GRB2:SOS1 activates RAS nucleotide exchange
Activated FGFR3:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange
Activated FGFR4:p-SHC1:GRB2:SOS1 activates RAS nucleotide exchange
Activated FGFR1:p-SHC1:GRB2:SOS1 activates RAS nucleotide exchange
Activated FGFR2:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange
Activated FGFR3:p-SHC1:GRB2:SOS1 activates RAS nucleotide exchange
Activated FGFR4:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange
Activated FGFR2 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange
Activated FGFR3 point, translocation and fusion mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange
Activated FGFR1 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange
Activated FGFR4 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange
RAS GAPs stimulate RAS GTPase activity
"Activator" RAF:YWHAB dimer binds RAS:GTP
RAS GEFs promote RAS nucleotide exchange
RAS:GTP:'activator' RAF homo/heterodimerizes with other RAF monomers
MAP2Ks and MAPKs bind to the activated RAF complex
MAP2Ks phosphorylate MAPKs
RAF phosphorylates MAP2K dimer
Dissociation of RAS:RAF complex
RAF/MAP kinase cascade
-
GTP-bound RAS recruits RAF and promotes RAF activation in the MAPK cascade.
"GTP-bound RAS recruits RAF (the MAPK kinase kinase), and promotes its dimerization and activation"
PEBP1 binds activated RAF1
PP2A dephosphorylates RAF1
PP5 dephosphorylates RAF1 S338
RAS GTPase mutants don't hydrolyze GTP
Loss-of-function NF1 variants don't stimulate RAS GTPase activity
RAS mutants bind inactive RAF
RAS:GTP:moderate kinase activity p-RAF complexes bind MAP2Ks and MAPKs
Moderate kinase activity BRAF mutants bind RAS:GTP
RAF is phosphorylated downstream of moderate kinase activity BRAF mutants
Activated MAP2Ks phosphorylate MAPKs downstream of inactive BRAF mutants
RAS:GTP:moderate kinase activity p-RAF complexes phosphorylate MAP2Ks
Activated MAP2Ks phosphorylate MAPKs downstream of moderate kinase activity BRAF mutants
Activated MAP2Ks phosphorylate MAPKs downstream of oncogenic RAS
RAF is phosphorylated downstream of oncogenic RAS
Mutant RAS:p-RAF complexes bind MAP2Ks and MAPKs
Mutant RAS:p-RAF complexes phosphorylate MAP2Ks
Inactive BRAF mutants bind mutant RAS:GTP
RAF is paradoxically phosphorylated downstream of kinase-inactive RAF
RAS:GTP:p-RAF complexes paradoxically bind MAP2Ks and MAPKs
RAS:GTP:inactive p-RAF complexes phosphorylate MAP2Ks
Dissociation of moderate activity BRAF complexes
Dissociation of oncogenic RAS:RAF complex
Dissociation of paradoxically activated RAS:BRAF complexes
Homo- or heterodimerization of RAF downstream of mutant RAS
RAS guanyl nucleotide exchange by MET-bound GRB2:SOS1
RAS guanyl nucleotide exchange by SOS1 associated with RANBP9 and MET
RAS guanyl nucleotide exchange by SOS1 bound to GRB2, SCH1-2 and MET
Moderate kinase activity BRAF mutants:RAS:GTP homo/heterodimerize
Inactive BRAF mutants:mutant RAS:GTP bind RAF1
Activated FGFR4:p-FRS:p-PTPN11 activates RAS nucleotide exchange
Activated FGFR2:p-FRS:p-PTPN11 activates RAS nucleotide exchange
Activated FGFR1:p-FRS:p-PTPN11 activates RAS nucleotide exchange
Activated FGFR3:p-FRS:p-PTPN11 activates RAS nucleotide exchange
RASA1 stimulates RAS GTPase activity
SOS1-mediated nucleotide exchange of RAS downstream of FLT3
PRKCZ recruits RAS in response to estrogen stimulation
PRKCZ stimulates RAS nucleotide exchange in response to estrogen
RAS guanyl-nucleotide exchange mediated by SOS1 in complex with GRB2 and ERBB2 homodimer:p-SHC1
ICMT methylates S-Farn RAS proteins
pro-RAS proteins are farnesylated
mature RAS proteins translocate to plasma membrane
-
RAS post-translational processing supports plasma membrane translocation.
"After farnesylation, C-terminal proteolysis, carboxymethylation and palmitoylation"
S-farn Me-HRAS, -NRAS and -KRAS4A are palmitoylated
RAS proteins are depalmitoylated
RCE1 cleaves S-Farn proRAS proteins
Mature S-Farn-Me KRAS4B translocates to plasma membrane
Intrinsic nucleotide exchange on RAS
RAS intrinsic GTPase activity hydrolyzes GTP to GDP
RAS GAP mutants aren't stimulated by GAPs
Raf dimer inhibitors bind RAF heterodimers
KRAS4B is phosphorylated on serine 181
S-Farn-Me KRAS4B binds calmodulin
pS181-S-Farn-Me KRAS4B translocates to the outer mitochondrial membrane
pS181-S-Farn-Me KRAS4B binds BCL2L1
Calmodulin dissociates KRAS4B from the plasma membrane
ARL2:GTP bind PDE6D on KRAS4B
PDE6D binds S-Farn-Me KRAS4B:CALM:4 Ca2+
KRAS4B recycles to the plasma membrane
Dissociation of RAS:RAF1 mutant complex
MAP2Ks and MAPKs bind to the activated mutant RAF1 complex
Phosphorylation of RAF1 mutants
RAF1 mutants show enhanced heterodimerization with BRAF
MAP2Ks phosphorylate MAPKs downstream of RAF1 mutants
RAF1 mutant complexes phosphorylate MAP2K dimer
Dual mechanism MAP2K inhibitors bind MAP2Ks
Dual mechanism MAPK inhibitors bind MAPKs
Single mechanism MAP2K inhibitors bind phosphorylated MAP2Ks
Single mechanism MAPK inhibitors bind phosphorylated MAPK
RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 KD mutants
RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 KD mutants and EGFR
RAS guanyl nucleotide exchange mediated by the p-6Y- ERBB2 ECD mutants:EGF:p-6Y-EGFR:p-SHC1:GRB2:SOS1
RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 ECD mutants and EGFR through GRB2
RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 TMD/JMD mutants
RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 TMD/JMD mutants and EGFR
p-KIT mutants:GRB2:SOS catalyzes nucleotide exchange on RAS
SOS-mediated nucleotide exchange on RAS downstream of PDGFRA extracellular domain dimers
SOS-mediated nucleotide exchange of RAS downstream of mutant PDGFR receptors
p-Y546,Y584-PTPN11 (in CSF3 dimer:2xp-4Y-CSF3R:LYN:p-Y-JAK1:p-JAK2:p-SYK:p-HCK:p-TYK2:SHC:GRB2:PTPN11) dephosphorylates KRAS
FLT3 mutants:GRB2:SOS1-mediated nucleotide exchange on RAS
SOS1-mediated nucleotide exchange of RAS downstream of FLT3 fusion mutants
UniProt record for human KRAS (P01116)
-
KRAS binds GDP/GTP and has intrinsic GTPase activity.
"Ras proteins bind GDP/GTP and possess intrinsic GTPase activity"
-
KRAS cycles between GDP-bound inactive and GTP-bound active forms.
"Alternates between an inactive form bound to GDP and an active form bound to GTP"
-
KRAS localizes to the cell membrane, endomembrane system, and cytosol.
"Cell membrane {ECO:0000269|PubMed:22431598, ECO:0000269|PubMed:23698361, ECO:0000269|PubMed:29239724}; Lipid-anchor"
Falcon deep research report on KRAS
-
KRAS intrinsic GTP hydrolysis is slow but real, with kcat ≈ 2×10^-4 s^-1, and is the central enzymatic activity of the molecular switch.
"A widely cited expert synthesis reports Ras intrinsic hydrolysis is slow (kcat ≈ 2×10−4 s−1), but it is a real enzymatic activity central to the molecular switch."
-
GAPs accelerate KRAS GTP hydrolysis up to ~10^5-fold via an arginine finger mechanism; oncogenic Gly12 mutants resist this stimulation.
"GAPs accelerate Ras hydrolysis (reported up to ~10^5-fold in expert synthesis) and do so by complementing the active site, including an external arginine ("arginine finger") concept; importantly, Gly12 oncogenic mutants are classically noted to resist such stimulation."
-
SOS-mediated nucleotide exchange proceeds via stabilization of a nucleotide-free Ras intermediate, established by the crystal structure of Ras–SOS complex.
"Primary structural evidence for Ras activation by SOS comes from the crystal structure of Ras in complex with the SOS catalytic region, indicating SOS stabilizes Ras in a nucleotide-free state, a mechanistic basis for GEF-driven exchange."
-
Switch I and switch II play distinct roles in SOS-catalyzed nucleotide exchange, with switch II anchoring Ras to SOS and switch I perturbation promoting GDP dissociation.
"Structure-guided mutagenesis further shows distinct roles for Ras switch I vs switch II: switch II interactions largely anchor Ras to SOS, while switch I perturbation disrupts the nucleotide-binding site to promote GDP dissociation."
-
GTP-loaded Ras directly engages effectors via switch I/II; the Ras–PI3Kγ crystal structure is a primary demonstration of nucleotide-dependent effector binding.
"A primary structural and functional demonstration of Ras effector engagement is the Ras–PI3Kγ complex: PI3Kγ is directly activated by GTP-loaded Ras, and the structure shows Ras uses switch I/II to bind the PI3Kγ Ras-binding domain."
-
KRAS4A palmitoylation at Cys180 enables reversible Golgi trafficking; combined farnesylation and palmitoylation increases membrane affinity by >100-fold.
"KRAS4A contains a palmitoylation site (Cys180) enabling reversible palmitoylation-dependent Golgi trafficking. Expert synthesis notes that farnesylation + palmitoylation can increase membrane affinity by >100-fold and acts as a Golgi "affinity trap" promoting vesicular delivery to the plasma membrane."
-
KRAS4B uses a polybasic HVR (net charge +8) for electrostatic plasma membrane association, distinct from KRAS4A's palmitoylation-dependent mechanism.
"KRAS4B lacks palmitoylatable cysteines and instead uses a lysine-rich polybasic HVR (reported net charge +8) to electrostatically stabilize plasma membrane association with anionic lipids."
-
PDE6D binds the KRAS4B prenyl group to support endomembrane-to-plasma-membrane trafficking; carboxymethylation loss reduces PDE6D affinity >35-fold.
"KRAS4B (and depalmitoylated prenylated cargo) can bind PDE6D to shield its prenyl group and support trafficking between endomembranes and plasma membrane. Quantitatively summarized evidence indicates that loss of KRAS4B carboxymethylation reduces PDE6D affinity by >35-fold, and a Ser181 phosphomimic (S181E) reduces affinity by >6-fold."
-
Downstream phenotypes from KRAS (proliferation, senescence, apoptosis, transcription, development) are context-dependent and mostly derived from mutant/overexpression models and should not be propagated as WT KRAS GO annotations without direct WT evidence.
"Downstream phenotypes (proliferation, senescence, apoptosis, transcriptional programs, developmental and immune/metabolic outcomes) are highly context dependent and often derived from mutant/overexpression models. These should not be propagated as WT KRAS GO BP annotations without direct WT evidence."